CN112851766A - 融合前rsv f蛋白和其用途 - Google Patents

融合前rsv f蛋白和其用途 Download PDF

Info

Publication number
CN112851766A
CN112851766A CN202110068562.XA CN202110068562A CN112851766A CN 112851766 A CN112851766 A CN 112851766A CN 202110068562 A CN202110068562 A CN 202110068562A CN 112851766 A CN112851766 A CN 112851766A
Authority
CN
China
Prior art keywords
rsv
protein
fusion
polypeptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110068562.XA
Other languages
English (en)
Chinese (zh)
Inventor
邝达平
B·S·格雷厄姆
J·S·麦克莱伦
M·G·乔伊斯
M·兼清
张宝山
J·博因顿
I·S·乔治夫
M·潘切拉
C·索托
S·斯来瓦特森
G·斯图尔特-琼斯
陈磊
陈曼
莊國瑜
J·戈尔曼
G·奥菲克
M·萨斯特里
杨永平
周同庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CN112851766A publication Critical patent/CN112851766A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18523—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
CN202110068562.XA 2013-03-13 2014-03-13 融合前rsv f蛋白和其用途 Pending CN112851766A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361780910P 2013-03-13 2013-03-13
US61/780,910 2013-03-13
US201361798389P 2013-03-15 2013-03-15
US61/798,389 2013-03-15
US201361857613P 2013-07-23 2013-07-23
US61/857,613 2013-07-23
US201361863909P 2013-08-09 2013-08-09
US61/863,909 2013-08-09
CN201480027499.3A CN105473604B (zh) 2013-03-13 2014-03-13 融合前rsv f蛋白和其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480027499.3A Division CN105473604B (zh) 2013-03-13 2014-03-13 融合前rsv f蛋白和其用途

Publications (1)

Publication Number Publication Date
CN112851766A true CN112851766A (zh) 2021-05-28

Family

ID=51625430

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110068562.XA Pending CN112851766A (zh) 2013-03-13 2014-03-13 融合前rsv f蛋白和其用途
CN201480027499.3A Active CN105473604B (zh) 2013-03-13 2014-03-13 融合前rsv f蛋白和其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480027499.3A Active CN105473604B (zh) 2013-03-13 2014-03-13 融合前rsv f蛋白和其用途

Country Status (21)

Country Link
US (5) US10017543B2 (enExample)
EP (2) EP4421177A3 (enExample)
JP (4) JP6703475B2 (enExample)
KR (3) KR102450375B1 (enExample)
CN (2) CN112851766A (enExample)
AU (5) AU2014243756B2 (enExample)
CA (1) CA2902877A1 (enExample)
DK (1) DK2970398T3 (enExample)
ES (1) ES2981623T3 (enExample)
FI (1) FI2970398T3 (enExample)
HR (1) HRP20240996T1 (enExample)
HU (1) HUE067333T2 (enExample)
LT (1) LT2970398T (enExample)
MX (2) MX385818B (enExample)
PL (1) PL2970398T3 (enExample)
PT (1) PT2970398T (enExample)
RS (1) RS65760B1 (enExample)
RU (1) RU2761631C2 (enExample)
SI (1) SI2970398T1 (enExample)
SM (1) SMT202400297T1 (enExample)
WO (1) WO2014160463A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118406159A (zh) * 2024-05-22 2024-07-30 苏州聚微生物科技有限公司 RSV pre-F截短体及其生产方法和应用
CN118496324A (zh) * 2024-05-22 2024-08-16 苏州聚微生物科技有限公司 RSV pre-F突变体及其生产方法和用途
CN120500351A (zh) * 2023-02-03 2025-08-15 维纳根有限责任公司 呼吸道合胞病毒mRNA疫苗

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
SMT202000145T1 (it) 2013-02-01 2020-05-08 Medimmune Llc Epitopi di proteina f di virus sinciziale respiratorio
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
WO2014160463A1 (en) 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
WO2014152534A1 (en) 2013-03-14 2014-09-25 Emory University Recombinant rsv with silent mutations, vaccines, and methods related thereto
US10633449B2 (en) 2013-03-27 2020-04-28 Cedars-Sinai Medical Center Treatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway
CN105188745B (zh) 2013-04-25 2019-10-18 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
CN105408348B (zh) * 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
EP3024483B1 (en) 2013-07-25 2020-01-15 Calder Biosciences Inc. Conformationally stabilized rsv pre-fusion f proteins
WO2015024668A2 (en) 2013-08-21 2015-02-26 Curevac Gmbh Respiratory syncytial virus (rsv) vaccine
JP2016533332A (ja) * 2013-09-24 2016-10-27 マサチューセッツ インスティテュート オブ テクノロジー 自己集合型ナノ粒子ワクチン
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
CN107406835A (zh) * 2015-01-20 2017-11-28 美利坚合众国,由健康及人类服务部部长代表 表达嵌合rsv/bpiv3f蛋白的重组人/牛副流感病毒3(b/hpiv3)及其用途
WO2016122414A1 (en) * 2015-01-29 2016-08-04 Agency For Science, Technology And Research Nanocapsules carrying chikungunya-associated peptides
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR20180026734A (ko) 2015-07-07 2018-03-13 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 융합-전 rsv f 폴리펩티드
CA2991002C (en) * 2015-07-07 2023-11-28 Janssen Vaccines & Prevention B.V. Vaccine against rsv
FR3041962B1 (fr) * 2015-10-01 2018-01-05 Lab Francais Du Fractionnement Procede d'enrichissement d'une preparation d'immunoglobulines en immunoglobulines anti-rsv et preparation ainsi enrichie
EP3718565B1 (en) 2015-10-22 2022-04-27 ModernaTX, Inc. Respiratory virus vaccines
TW201729836A (zh) * 2015-10-22 2017-09-01 現代公司 呼吸道融合病毒疫苗
KR20180085730A (ko) 2015-10-29 2018-07-27 에모리 유니버시티 키메라 rsv, 면역원성 조성물, 및 사용 방법
KR102136678B1 (ko) 2015-12-23 2020-07-22 화이자 인코포레이티드 Rsv f 단백질 돌연변이체
WO2017161342A1 (en) 2016-03-17 2017-09-21 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through rnaset2
EP3436064A1 (en) * 2016-03-29 2019-02-06 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion rsv f proteins and their use
US10729757B2 (en) 2016-04-05 2020-08-04 Janssen Vaccines & Prevention B.V. Vaccine against RSV
CN116063551A (zh) 2016-04-05 2023-05-05 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f蛋白
IL245059A0 (en) 2016-04-12 2016-06-30 Technion Res & Dev Foundation Electrospun scaffolds from extracellular matrix
BR112018074483A2 (pt) 2016-05-30 2019-03-19 Janssen Vaccines & Prevention B.V. proteínas f do rsv pré-fusão estabilizadas
WO2018005558A1 (en) 2016-06-27 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
CN106119287B (zh) * 2016-08-29 2019-10-11 广东华南疫苗股份有限公司 一种表达呼吸道合胞病毒f蛋白的重组载体及方法
US10842862B2 (en) 2016-10-03 2020-11-24 University Of Massachusetts Methods for immunizing pre-immune subjects against respiratory syncytial virus (RSV)
EP3532096B1 (en) 2016-10-25 2023-02-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Prefusion piv f immunogens and their use
JP7194104B2 (ja) 2016-10-26 2022-12-21 シーダーズ―シナイ メディカル センター 抗ｔｌ１ａモノクローナル抗体の中和
TWI683826B (zh) * 2016-11-22 2020-02-01 國立臺灣大學 重組ｒｓｖ抗原
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CN108265079A (zh) * 2017-01-02 2018-07-10 刘昕 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
WO2018175518A1 (en) * 2017-03-22 2018-09-27 The Scripps Research Institute Mini-protein immunogens displayng neutralization epitopes for respiratory syncytial virus (rsv)
MX2019011869A (es) 2017-04-04 2020-01-09 Univ Washington Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
EP3630176A1 (en) 2017-05-30 2020-04-08 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
KR20200018483A (ko) * 2017-06-14 2020-02-19 비로메틱스 아게 호흡기 합포체 바이러스에 대한 방어를 위한 고리형 펩티드
WO2019032480A1 (en) * 2017-08-07 2019-02-14 Avatar Medical, Llc PROTEINS F PRE-FUSION OF RSV STABILIZED IN TERMS OF CONFORMATION
JP2020533367A (ja) 2017-09-15 2020-11-19 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖに対する免疫の安全な誘導方法
JP2019092481A (ja) * 2017-11-27 2019-06-20 国立大学法人東京工業大学 ヘテロタンパク質ケージ
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
EP3746090A4 (en) * 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA Vaccines
AU2019212237B2 (en) * 2018-01-29 2024-12-12 Merck Sharp & Dohme Llc Stabilized RSV F proteins and uses thereof
US11771755B2 (en) 2018-02-28 2023-10-03 University Of Washington Self-asssembling nanostructure vaccines
US11623004B2 (en) 2018-03-16 2023-04-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions and methods for vaccination against respiratory syncytial virus infection
CN112512564A (zh) 2018-04-03 2021-03-16 赛诺菲 铁蛋白蛋白
EP3773703A1 (en) * 2018-04-03 2021-02-17 Sanofi Antigenic influenza-ferritin polypeptides
CA3095175A1 (en) * 2018-04-03 2019-10-10 Sanofi Antigenic respiratory syncytial virus polypeptides
EP3773708A2 (en) 2018-04-03 2021-02-17 Sanofi Antigenic epstein barr virus polypeptides
EP4227319B1 (en) * 2018-04-17 2025-11-26 CureVac SE Novel rsv rna molecules and compositions for vaccination
KR102763158B1 (ko) 2018-04-25 2025-02-04 프로메테우스 바이오사이언시즈, 인크. 최적화된 항tl1a 항체
KR20210013571A (ko) 2018-05-04 2021-02-04 스파이바이오테크 리미티드 백신 조성물
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
MX2021001129A (es) * 2018-07-31 2021-07-02 Glaxosmithkline Biologicals Sa Metodo de purificacion de antigenos.
AU2019315602A1 (en) 2018-08-03 2021-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nipah virus immunogens and their use
JP2021533162A (ja) 2018-08-07 2021-12-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロセス及びワクチン
CA3117275A1 (en) * 2018-11-13 2020-05-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
CN113646330A (zh) * 2018-11-14 2021-11-12 鲁比克治疗股份有限公司 工程化cd25多肽及其用途
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
AU2020227545B2 (en) 2019-02-28 2023-10-19 Km Biologics Co., Ltd. RSV F/G chimeric vaccine
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
US20220306697A1 (en) 2019-09-04 2022-09-29 University Of Washington Self-Assembling Protein Nanostructures Displaying Paramyxovirus and/or Pneumovirus F Proteins and Their Use
KR20220103721A (ko) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
CA3164343A1 (en) * 2019-12-11 2021-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mumps and measles virus immunogens and their use
KR20220116516A (ko) * 2019-12-23 2022-08-23 미쓰비시 타나베 파마 코퍼레이션 변이형 rsv f 단백질 및 그 이용
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
IL295148A (en) * 2020-01-30 2022-09-01 Modernatx Inc Respiratory virus immunizing compositions
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
CN116096407A (zh) * 2020-04-29 2023-05-09 美国政府(由卫生和人类服务部的部长所代表) 重组人偏肺病毒f蛋白及其用途
MX2022015040A (es) * 2020-05-29 2023-02-27 Univ Texas Proteina espicular (s) del coronavirus geneticamente manipulada y metodos de uso de la misma.
CA3170740A1 (en) 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
WO2021249009A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Rsv vaccine compositions, methods, and uses thereof
JP2022023813A (ja) 2020-07-27 2022-02-08 ファイザー・インク 組換え生産されたｒｓｖタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良
JP2022023814A (ja) 2020-07-27 2022-02-08 ファイザー・インク 組換え生産された三量体型のｒｓｖタンパク質の精製方法
CN112226444B (zh) * 2020-08-25 2022-11-04 北京交通大学 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
CN116615235A (zh) 2020-10-09 2023-08-18 得克萨斯州大学系统董事会 融合前稳定的hmpv f蛋白
JP2023547197A (ja) 2020-10-28 2023-11-09 サノフィ・パスツール Ｔｌｒ４アゴニストを含有するリポソーム、その製造および使用
CN112592928B (zh) * 2020-12-31 2021-08-31 北京鼎成肽源生物技术有限公司 冠状病毒的融合基因、融合蛋白、重组载体、通用型dc疫苗及其制备方法
JP2024509756A (ja) * 2021-02-19 2024-03-05 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された融合前ｒｓｖ ｆｂ抗原
CN117500520A (zh) 2021-04-02 2024-02-02 圣康丁昂伊夫利纳凡尔赛大学 包含抗原和含有Al-MOF的佐剂的免疫原性组合物
US12304929B2 (en) * 2021-04-12 2025-05-20 Sk Bioscience Co., Ltd. Recombinant RSV live vaccine strain and the preparing method thereof
US20240200099A1 (en) * 2021-04-15 2024-06-20 Merck Sharp & Dohme Llc Rotavirus vectors for heterologous gene delivery
JP2024531150A (ja) * 2021-08-10 2024-08-29 アイコサバックス， インコーポレイテッド 呼吸器多核体ウイルスに対するウイルス様粒子ワクチン
EP4410969A1 (en) * 2021-09-29 2024-08-07 SK Bioscience Co., Ltd. Recombinant live attenuated rsv vaccine strain and production method therefor
JP2024542478A (ja) * 2021-11-19 2024-11-15 アールエヌエーイミューン、インコーポレイテッド リボ核酸呼吸器合胞体ウイルス（ｒｓｖ）ワクチンの組成物および方法
KR102785012B1 (ko) * 2021-12-14 2025-03-20 경희대학교 산학협력단 Rsv 항원 단백질을 포함하는 바이러스 유사입자 및 이를 이용한 백신
CN117715923A (zh) * 2022-04-29 2024-03-15 北京新合睿恩生物医疗科技有限公司 Rsv f蛋白突变体及其应用
JP2025515966A (ja) * 2022-05-31 2025-05-20 ＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｊａｐａｎ株式会社 改変ワクチン設計の開発
WO2023237649A1 (en) * 2022-06-10 2023-12-14 Glaxosmithkline Biologicals Sa Rsv vaccination with trimeric rsv f fusion protein
WO2024041772A1 (en) * 2022-08-22 2024-02-29 Glaxosmithkline Biologicals Sa Rsv-f proteins
EP4593876A2 (en) 2022-09-29 2025-08-06 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
CN116478296B (zh) * 2022-10-17 2024-02-23 厦门大学 截短的呼吸道合胞病毒f蛋白及其用途
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
CN120153078A (zh) 2022-10-27 2025-06-13 辉瑞大药厂 编码rsv-f的rna分子及含所述rna分子的疫苗
JP2025537539A (ja) * 2022-11-04 2025-11-18 サノフィ パスツール インコーポレイテッド 呼吸器合胞体ウイルスｒｎａワクチン接種
EP4615980A1 (en) * 2022-11-09 2025-09-17 Nykode Therapeutics ASA Co-expression of constructs and polypeptides
KR102531775B1 (ko) 2022-11-11 2023-05-15 대한민국 Rsv f 항체 또는 이의 항원 결합 단편
CN116284266B (zh) * 2022-11-21 2024-01-19 怡道生物科技(苏州)有限公司 突变型呼吸道合胞病毒融合前f蛋白及其应用
WO2024115561A1 (en) * 2022-12-01 2024-06-06 Glaxosmithkline Biologicals Sa Vaccination against rsv
WO2024127181A1 (en) 2022-12-11 2024-06-20 Pfizer Inc. Immunogenic compositions against influenza and rsv
EP4652184A2 (en) * 2023-01-17 2025-11-26 The Scripps Research Institute Engineered paramyxovirus soluble fusion (f) proteins and related vaccines
CN120548194A (zh) 2023-01-18 2025-08-26 辉瑞公司 针对呼吸道疾病的疫苗
WO2024164020A2 (en) * 2023-02-03 2024-08-08 The Trustees Of Columbia University In The City Of New York Methods of inhibiting paramyxoviridae fusion to a target cell
CN121013729A (zh) * 2023-02-21 2025-11-25 Msd国际商务股份有限公司 不具有异源三聚化结构域的稳定化的三聚rsv融合蛋白
WO2024175040A1 (en) * 2023-02-22 2024-08-29 Everest Medicines (China) Co., Ltd. RSV mRNA VACCINES
EP4644550A1 (en) * 2023-03-17 2025-11-05 WestVac Biopharma Co., Ltd. Vaccine against respiratory syncytial virus infection
CN116536357A (zh) * 2023-04-17 2023-08-04 中国医学科学院输血研究所 构建CRISPR/Cas12a中sgRNA剪切活性筛选系统的方法
CN118108812B (zh) * 2023-05-04 2025-04-15 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
CN118994329A (zh) * 2023-05-18 2024-11-22 北京微星生物科技有限公司 融合前rsv f蛋白及其应用
CN117050149B (zh) * 2023-05-19 2025-12-12 珠海丽凡达生物技术有限公司 包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
CN119019514A (zh) * 2023-05-25 2024-11-26 江苏瑞科生物技术股份有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
WO2024251281A1 (zh) * 2023-06-07 2024-12-12 四川三叶草生物制药有限公司 Rsv疫苗组合物、方法及其用途
WO2024256637A1 (en) * 2023-06-16 2024-12-19 Glaxosmithkline Biologicals Sa Cysteine-substituted rsv-f proteins
TW202515531A (zh) 2023-07-07 2025-04-16 美商輝瑞股份有限公司 兩親性ｔｌｒ７／８佐劑及其用途
CN119431524A (zh) * 2023-08-07 2025-02-14 北京新合睿恩生物医疗科技有限公司 Rsv融合前构象f蛋白的突变体及其应用
WO2025092933A1 (zh) * 2023-10-31 2025-05-08 上海蓝鹊生物医药有限公司 一种rsv抗原、核酸、重组表达载体、药物组合物及其应用
CN120022355A (zh) * 2023-11-22 2025-05-23 长春百克生物科技股份公司 一种mRNA疫苗及其应用
CN117304278B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025127857A1 (ko) * 2023-12-15 2025-06-19 에스케이바이오사이언스(주) 변이 rsv 단백질
KR102816014B1 (ko) * 2023-12-20 2025-06-02 에스케이바이오사이언스(주) Rsv 의 가용성 f 단백질을 생성하기 위한 재조합 전구체 폴리펩티드 및 이의 이용
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
CN117586425B (zh) * 2024-01-19 2024-06-14 北京安百胜生物科技有限公司 一种重组呼吸道合胞病毒颗粒抗原其制备方法和应用
CN117567652B (zh) * 2024-01-19 2024-05-14 北京安百胜生物科技有限公司 一种重组呼吸道合胞病毒颗粒抗原
CN117586357B (zh) * 2024-01-19 2024-07-09 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
CN117645655B (zh) * 2024-01-26 2024-05-24 普大生物科技(泰州)有限公司 一种肺炎球菌多糖-rsv重组蛋白结合疫苗及其制备方法
WO2025163460A2 (en) 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2025186719A1 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions and uses thereof
CN118440937B (zh) * 2024-04-09 2025-02-25 嘉译生物医药(杭州)有限公司 新型的人合胞病毒RSV B mRNA疫苗
CN118580323B (zh) * 2024-05-22 2025-06-17 苏州聚微生物科技有限公司 Rsv融合前f蛋白的突变体及其制备和应用
CN119074910A (zh) * 2024-08-30 2024-12-06 中国医学科学院病原生物学研究所 以麻疹减毒活疫苗为载体的重组呼吸道合胞病毒疫苗及其制备方法
CN119176859B (zh) * 2024-11-26 2025-03-14 北京成大天和生物科技有限公司 呼吸道合胞病毒f蛋白突变体及其应用
CN119371496B (zh) * 2024-12-26 2025-03-25 北京华诺泰生物医药科技有限公司 一种呼吸道合胞病毒f蛋白突变体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336955C (en) * 1988-09-20 1995-09-12 Peter R. Paradiso Respiratory syncytial virus: vaccines and diagnostic assays
CA2293694A1 (en) * 1998-06-10 1999-12-16 Incyte Pharmaceuticals, Inc. New carboxypeptidase inhibitor
WO2012158613A1 (en) * 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US472209A (en) 1892-04-05 Vacuum-pan
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
CA1236641A (en) 1984-07-06 1988-05-10 Motoaki Tanaka Copolymer of lactic acid and glycolic acid and method for producing same
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
CA2129514A1 (en) 1992-03-12 1993-09-16 M. Amin Khan Controlled released acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
CA2142007C (en) 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
ES2109685T5 (es) 1993-03-23 2005-09-01 Smithkline Beecham Biologicals S.A. Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
DE69435108D1 (de) 1993-07-13 2008-08-14 Centelion Defekte adenovirus-vektoren und deren verwendung in der gentherapie
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
AU700485B2 (en) 1993-11-17 1999-01-07 Om Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6020182A (en) 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
ATE309385T1 (de) 2000-06-28 2005-11-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
US20030232061A1 (en) 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
MXPA03008154A (es) 2001-03-09 2004-11-12 Id Biomedical Corp Quebec Novedoso adyuvante de vacuna de proteosoma-liposacarido.
US7157465B2 (en) 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
EP1425045A4 (en) 2001-09-13 2004-11-10 Genvec Inc ADENOVIRAL VECTOR AND RELEVANT SYSTEM AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2003029416A2 (en) 2001-10-01 2003-04-10 Uab Research Foundation Recombinant respiratory syncytial viruses with deleted surface glycoprotein genes and uses thereof
AU2002343728A1 (en) 2001-11-16 2003-06-10 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor pathways
TWI405851B (zh) 2002-02-21 2013-08-21 Medimmune Llc 間質肺病毒株及其作為疫苗調配物及作為表現抗原性序列之載體之應用
WO2004010935A2 (en) 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
EP1558747B1 (en) 2002-10-16 2009-10-14 The Scripps Research Institute Glycoprotein synthesis
WO2004071459A2 (en) 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
EP2494986A1 (en) 2003-04-25 2012-09-05 MedImmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
MXPA05011268A (es) 2003-04-25 2006-06-20 Medimmune Vaccines Inc Sistemas de expresion de virus de parainfluenza recombinante y vacunas que comprenden antigenos heterologos derivados del metaneumovirus.
US8637234B2 (en) 2004-04-16 2014-01-28 Uab Research Foundation Molecular scaffolds for HIV-1 epitopes
US8647818B2 (en) 2005-02-18 2014-02-11 UAB Research Foundation, University of Alabama—Birmingham Molecular scaffolds for HIV-1 immunogens
CA2600484A1 (en) 2005-03-10 2006-09-21 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
US7728106B2 (en) 2005-07-01 2010-06-01 University Of Maryland Biotechnology Institute HIV-1 glycopeptides and derivatives; preparation and applications thereof
CA2647632C (en) 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
US20100068217A1 (en) 2006-08-25 2010-03-18 Kwong Peter D Epitope-transplant scaffolds and their use
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2009012155A2 (en) 2007-07-13 2009-01-22 Medimmune, Llc Preparation of negative-stranded rna viruses by electroporation
EP4206231A1 (en) * 2007-12-24 2023-07-05 ID Biomedical Corporation of Quebec Recombinant rsv antigens
HRP20221475T3 (hr) 2007-12-27 2023-01-06 Universität Zürich Replikacijski defektni vektori arenavirusa
US20110318376A1 (en) * 2008-12-24 2011-12-29 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
BRPI1007744A2 (pt) 2009-05-12 2017-06-27 Transgene Sa método para a produção e purificação de um ortopoxvírus do tipo selvagem, ortopoxvírus do tipo selvagem, composição farmacêutica, uso de um ortopoxvírus do tipo selvagem e uso de uma linhagem de células aviárias imortalizadas
ES2583257T3 (es) 2009-06-24 2016-09-20 Glaxosmithkline Biologicals S.A. Antígenos recombinantes del VSR
WO2010149743A2 (en) 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine
ES2563730T3 (es) 2009-07-15 2016-03-16 Glaxosmithkline Biologicals S.A. Composiciones de proteína RSV F y procedimientos de fabricación de las mismas
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
BR112012008173B1 (pt) 2009-10-06 2021-12-07 Medimmune Ltd Anticorpo monoclonal humano recombinante, sintético ou isolado ou uma parte funcional do mesmo que se liga especificamente à proteína f do vírus sincicial respiratório, sequência de ácido nucleico isolada ou um equivalente funcional da mesma, vetor, combinação, composição farmacêutica, usos dos mesmos e método para produzir um anticorpo ou parte funcional do mesmo
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
CN102210860B (zh) 2011-05-31 2012-11-21 昆明理工大学 一种结核分枝杆菌tb10．4-f1融合蛋白疫苗及制备方法
ES2395677B1 (es) 2011-07-29 2013-12-26 Instituto De Salud Carlos Iii Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma.
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
EA201590683A1 (ru) * 2012-11-20 2015-11-30 Глаксосмитклайн Байолоджикалс С.А. Тримеры rsv f, предшествующие слиянию
WO2014160463A1 (en) * 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
JP6462599B2 (ja) 2013-03-15 2019-01-30 シャアメン ユニバーシティ Ｒｓｖ融合タンパク質のエピトープ及びそのエピトープを認識する抗体
CN105188745B (zh) 2013-04-25 2019-10-18 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336955C (en) * 1988-09-20 1995-09-12 Peter R. Paradiso Respiratory syncytial virus: vaccines and diagnostic assays
CA2293694A1 (en) * 1998-06-10 1999-12-16 Incyte Pharmaceuticals, Inc. New carboxypeptidase inhibitor
WO2012158613A1 (en) * 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
王晓燕;彭慧琴;: "人巨细胞病毒包膜糖蛋白gB、gH结构、分型及生物学活性", 中国卫生检验杂志, no. 10 *
陈历胜 , 陈本川: "抗呼吸道合胞病毒新型化疗剂", 国外医药.合成药.生化药.制剂分册, no. 05 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120500351A (zh) * 2023-02-03 2025-08-15 维纳根有限责任公司 呼吸道合胞病毒mRNA疫苗
CN118406159A (zh) * 2024-05-22 2024-07-30 苏州聚微生物科技有限公司 RSV pre-F截短体及其生产方法和应用
CN118496324A (zh) * 2024-05-22 2024-08-16 苏州聚微生物科技有限公司 RSV pre-F突变体及其生产方法和用途
CN118496324B (zh) * 2024-05-22 2025-10-21 苏州聚微生物科技有限公司 RSV pre-F突变体及其生产方法和用途

Also Published As

Publication number Publication date
RU2021132097A (ru) 2022-03-03
KR20150127102A (ko) 2015-11-16
AU2025203614A1 (en) 2025-06-12
EP2970398A1 (en) 2016-01-20
US11130785B2 (en) 2021-09-28
BR112015022375A2 (pt) 2017-10-10
RU2015142981A (ru) 2017-04-17
AU2018282476B2 (en) 2020-12-10
JP7503588B2 (ja) 2024-06-20
US20240018193A1 (en) 2024-01-18
PL2970398T3 (pl) 2024-09-16
EP2970398A4 (en) 2016-08-24
HRP20240996T1 (hr) 2024-10-25
MX2015013065A (es) 2016-06-06
JP2020089384A (ja) 2020-06-11
CA2902877A1 (en) 2014-10-02
US20180319846A1 (en) 2018-11-08
AU2018282476A1 (en) 2019-01-24
WO2014160463A1 (en) 2014-10-02
WO2014160463A8 (en) 2015-10-08
AU2023200712A1 (en) 2023-03-09
MX2021010519A (es) 2021-10-01
EP2970398B1 (en) 2024-05-08
ES2981623T3 (es) 2024-10-10
BR112015022375A8 (pt) 2018-01-23
US10017543B2 (en) 2018-07-10
AU2021201468B2 (en) 2022-11-24
US20220002351A1 (en) 2022-01-06
EP4421177A2 (en) 2024-08-28
DK2970398T3 (da) 2024-08-05
JP7043530B2 (ja) 2022-03-29
EP4421177A3 (en) 2024-12-18
JP2024107243A (ja) 2024-08-08
KR20250023601A (ko) 2025-02-18
JP6703475B2 (ja) 2020-06-03
KR102766946B1 (ko) 2025-02-12
KR20220139415A (ko) 2022-10-14
MX385818B (es) 2025-03-18
SMT202400297T1 (it) 2024-09-16
US20250368690A1 (en) 2025-12-04
CN105473604B (zh) 2021-01-22
HUE067333T2 (hu) 2024-10-28
AU2014243756A1 (en) 2015-09-17
SI2970398T1 (sl) 2024-09-30
AU2023200712B2 (en) 2025-02-20
RU2761631C2 (ru) 2021-12-13
RU2015142981A3 (enExample) 2018-03-14
CN105473604A (zh) 2016-04-06
JP2022089818A (ja) 2022-06-16
US20160046675A1 (en) 2016-02-18
US11981707B2 (en) 2024-05-14
FI2970398T3 (fi) 2024-08-06
JP2016519658A (ja) 2016-07-07
LT2970398T (lt) 2024-08-12
RS65760B1 (sr) 2024-08-30
AU2021201468A1 (en) 2021-03-25
KR102450375B1 (ko) 2022-10-04
PT2970398T (pt) 2024-06-07
AU2014243756B2 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
JP7503588B2 (ja) 融合前ｒｓｖ ｆタンパク質およびそれらの使用
US10858400B2 (en) Prefusion RSV F proteins and their use
US12233124B2 (en) Recombinant metapneumovirus f proteins and their use
US11084850B2 (en) Recombinant prefusion RSV F proteins and uses thereof
US20230174587A1 (en) Recombinant human metapneumovirus f proteins and their use
BR112015022375B1 (pt) Imunógenos isolados de proteína f de rsv e seu uso, partícula similar a vírus, nanopartícula de proteína, molécula de ácido nucleico, vetor, célula hospedeira isolada bacteriana ou de levedura, composição imunogênica e kit

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination